Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics.

Détails

Ressource 1Télécharger: serval:BIB_220A827E8278.P001 (190.47 [Ko])
Etat: Public
Version: de l'auteur
Licence: Non spécifiée
It was possible to publish this article open access thanks to a Swiss National Licence with the publisher.
ID Serval
serval:BIB_220A827E8278
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics.
Périodique
European journal of nuclear medicine and molecular imaging
Auteur(s)
Antonescu C., Bischof Delaloye A., Kosinski M., Monnin P., Schaffland A.O., Ketterer N., Grannavel C., Kovacsovics T., Verdun F.R., Buchegger F.
ISSN
1619-7070
Statut éditorial
Publié
Date de publication
2005
Peer-reviewed
Oui
Volume
32
Numéro
8
Pages
943-51
Langue
anglais
Notes
Publication types: Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't - Publication Status: ppublish
Résumé
PURPOSE: It is generally assumed that the biodistribution and pharmacokinetics of radiolabelled antibodies remain similar between dosimetric and therapeutic injections in radioimmunotherapy. However, circulation half-lives of unlabelled rituximab have been reported to increase progressively after the weekly injections of standard therapy doses. The aim of this study was to evaluate the evolution of the pharmacokinetics of repeated 131I-rituximab injections during treatment with unlabelled rituximab in patients with non-Hodgkin's lymphoma (NHL). METHODS: Patients received standard weekly therapy with rituximab (375 mg/m2) for 4 weeks and a fifth injection at 7 or 8 weeks. Each patient had three additional injections of 185 MBq 131I-rituximab in either treatment weeks 1, 3 and 7 (two patients) or weeks 2, 4 and 8 (two patients). The 12 radiolabelled antibody injections were followed by three whole-body (WB) scintigraphic studies during 1 week and blood sampling on the same occasions. Additional WB scans were performed after 2 and 4 weeks post 131I-rituximab injection prior to the second and third injections, respectively. RESULTS: A single exponential radioactivity decrease for WB, liver, spleen, kidneys and heart was observed. Biodistribution and half-lives were patient specific, and without significant change after the second or third injection compared with the first one. Blood T(1/2)beta, calculated from the sequential blood samples and fitted to a bi-exponential curve, was similar to the T(1/2) of heart and liver but shorter than that of WB and kidneys. Effective radiation dose calculated from attenuation-corrected WB scans and blood using Mirdose3.1 was 0.53+0.05 mSv/MBq (range 0.48-0.59 mSv/MBq). Radiation dose was highest for spleen and kidneys, followed by heart and liver. CONCLUSION: These results show that the biodistribution and tissue kinetics of 131I-rituximab, while specific to each patient, remained constant during unlabelled antibody therapy. RIT radiation doses can therefore be reliably extrapolated from a preceding dosimetry study.
Mots-clé
Antibodies, Monoclonal, Body Burden, Drug Administration Schedule, Female, Humans, Infusions, Intralesional, Injections, Intralesional, Kinetics, Lymphoma, Non-Hodgkin, Male, Metabolic Clearance Rate, Middle Aged, Organ Specificity, Radiometry, Radiopharmaceuticals, Radiotherapy Dosage, Relative Biological Effectiveness, Tissue Distribution, Whole-Body Counting
Pubmed
Web of science
Open Access
Oui
Création de la notice
25/01/2008 12:22
Dernière modification de la notice
01/10/2019 7:17
Données d'usage